Takeda Pharmaceutical Company
Open
$15.94
Prev. Close
$15.94
High
$15.94
Low
$15.91
Market Snapshot
$50.26B
-52.8
0.44
$30.18B
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 47,455 full-time employees. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
Recently from Cashu
Takeda Pharmaceutical Reports Resilient Financial Performance Amid VYVANSE Challenges and Strategic Growth Initiatives
Takeda Pharmaceutical Company (Ticker: TAK) continues to demonstrate robust financial health in the competitive pharmaceutical market, despite facing challenges from generic competition that affects i…
Eli Lilly Expands Neuroscience Portfolio with Centessa Acquisition, Challenging Takeda’s Position
Eli Lilly's Strategic Expansion in Neuroscience: Implications for the Competitive Landscape Eli Lilly and Company takes a significant step in the neuroscience space with its recent announcement to acq…
Takeda Pharmaceutical Company Invests in Innovative Mental Health Therapies to Address Global Demand
Takeda Pharmaceutical Company Targets Innovations in Mental Health Treatments In a landscape where mental health disorders impact over 970 million individuals globally, Takeda Pharmaceutical Company r…
Helus Pharma's NSAs: Pioneering Innovations in Mental Health Therapeutics Market Growth
Innovative Serotonergic Therapies on the Rise in Mental Health Treatment Helus Pharma is making significant strides in the booming mental health therapeutics market, which is set to surpass $40 billio…